Open AccessLamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children
Author(s) -
H Green,
D M Gibb,
A S Walker,
D Pillay,
K Butler,
F Candeias,
G Castelli-Gattinara,
A Compagnucci,
M Della Negra,
A de Rossi,
C Feiterna-Sperling,
C Giaquinto,
L Harper,
J Levy,
Y Saidi,
U Wintergerst
Publication year - 2007
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3280e087e7
Subject(s) - lamivudine , abacavir , zidovudine , nelfinavir , medicine , reverse transcriptase inhibitor , virology , sida , viral load , human immunodeficiency virus (hiv) , viral disease , antiretroviral therapy , virus , hepatitis b virus
To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial.